About TRV045

Trevena is currently developing a novel sphingosine-1-phosphate (S1P) receptor modulator, TRV045, as a non-opioid treatment for various CNS disorders.

S1P receptors are located throughout the body, including the central nervous system, where they are believed to play a role in modulating neurotransmission and membrane excitability.

Trevena's discovery efforts have provided innovative insight into the function of the S1P receptor, resulting in a family of compounds that are capable of engaging this receptor in a more selective manner that does not produce immunosuppression or alter lymphocyte trafficking. In a preclinical model of chemotherapy-induced peripheral neuropathy, TRV045 demonstrated activity with reduced associated lymphopenia.